Phathom posts Q1 net loss $82.9M, revenue $1.9M; VOQUEZNA prescriptions top 17,500

Phathom Pharmaceuticals, Inc.

2024-Q1 EPS reported -$1.42 revenue$1,912,000

Net loss GAAP $82.9M (non-GAAP adj. net loss $64.8M) vs $37.8M loss Q1 2023; revenue $1.9M from VOQUEZNA launch.
Over 17,500 prescriptions dispensed launch-to-date (+361% vs last quarterly report); >3,800 prescribers.
SG&A expenses $62.0M (up from $18.6M YoY) reflecting commercial infrastructure build and marketing.
Cigna added VOQUEZNA to formularies; commercial coverage now ~48% of U.S. commercial lives (~72M covered).
FDA PDUFA date July 19, 2024 for NERD indication; Phase 3 NERD and Phase 2 EoE studies planned later in 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Phathom Pharmaceuticals, Inc. reported the first quarter of 2024 results: revenue Net revenues for the first quarter 2024 were $1.9 million, net income Net loss for the first quarter 2024 was $82.9 million.

Period: the first quarter of 2024
Revenue: Net revenues for the first quarter 2024 were $1.9 million
Net income: Net loss for the first quarter 2024 was $82.9 million
Result: reported results

Exact text from the filing

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today reported financial results for the first quarter of 2024

View on SEC.gov

Browse all earnings releases →

Phathom Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-134793

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.